PRFX - PainReform Advances Pain Relief Solution PRF-110 in Phase 3 Trial to Combat Opioid Crisis

(NewsDirect)

PainReform CEO Ilan Hadar joined SteveDarling from Proactive to discuss the company at the forefront ofaddressing the opioid crisis in the United States, is developingPRF-110, an innovative post-operative pain treatment designed as analternative to traditional opioids. PRF-110 is applied directly bysurgeons during procedures, offering patients up to 72 hours ofcontinuous pain relief, potentially eliminating the need foradditional pain medications post-surgery.

The company is currently advancing a Phase III study in Texas toevaluate the effectiveness and safety of PRF-110. The study, whichbegan in October 2023, has already seen significant progress with morethan 50% of the target 400 patients enrolled. Completion of patientenrollment is expected by mid-year, and the study results areanticipated in the third quarter of the same year. A successfuloutcome from this study could pave the way for another Phase III trialfocusing on soft tissue applications, slated to start in early 2025,with results expected by 2026.

Should the upcoming trialsconfirm PRF-110’s efficacy and safety, PainReform plans to submit aNew Drug Application in 2026. The company recognizes the significantmarket potential for non-opioid post-operative pain treatments, anarea currently underexplored, and is positioning PRF-110 as a keyplayer in transforming pain management practicespost-surgery.

Contact Details

Proactive NorthAmerica

+1 604-688-8158

na-editorial@proactiveinvestors.com

Copyright (c) 2024 TheNewswire - All rights reserved.